MedPath

Adalimumab-ryvk

Adalimumab-ryvk is biosimilarto HUMIRA(adalimumab).

Approved
Approval ID

dce1590f-9e47-4c4d-9437-cfb18b779a75

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 28, 2025

Manufacturers
FDA

Quallent Pharmaceuticals Health LLC

DUNS: 815564528

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

adalimumab-ryvk

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code82009-156
Application NumberBLA761299
Product Classification
M
Marketing Category
C73585
G
Generic Name
adalimumab-ryvk
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateFebruary 28, 2025
FDA Product Classification

adalimumab-ryvk

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code82009-158
Application NumberBLA761299
Product Classification
M
Marketing Category
C73585
G
Generic Name
adalimumab-ryvk
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateFebruary 28, 2025
FDA Product Classification

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Adalimumab-ryvk - FDA Drug Approval Details